8-KRegulation FDExhibits & Filings

Guardant Health, Inc. 8-K Report, Regulation FD Disclosure (May 9, 2023)

Filed May 9, 2023For Securities:GH

Summary

Guardant Health, Inc. (GH) filed an 8-K on May 9, 2023, to disclose additional data from its ECLIPSE study regarding its Shield™ blood screening test for colorectal cancer (CRC) in average-risk adults. This presentation at the 2023 Digestive Disease Week (DDW) expands upon the top-line results initially announced in December 2022, providing further insights into the test's performance. Investors should note that this information is being furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act. However, the supplemental data from the ECLIPSE study is crucial as it pertains to the performance of Guardant's Shield test, a key product for the company's expansion into the average-risk screening market. The detailed data presented at DDW could influence investor perceptions of the test's clinical utility and commercial potential.

Key Highlights

  • 1Guardant Health presented additional data on its Shield™ blood screening test for colorectal cancer at the 2023 Digestive Disease Week (DDW).
  • 2The new data elaborates on the top-line results of the ECLIPSE study, initially announced in December 2022.
  • 3The Shield™ test is designed for colorectal cancer screening in average-risk adults.
  • 4The press release containing the data is furnished as an exhibit to the 8-K filing.
  • 5The information is provided under Regulation FD and is not considered 'filed' under Section 18 of the Exchange Act.

Frequently Asked Questions

The main purpose of this 8-K filing is to disclose additional data from Guardant Health's ECLIPSE study concerning its Shield™ blood screening test for colorectal cancer, presented at the 2023 Digestive Disease Week (DDW).

The ECLIPSE study data is significant because it provides further evidence on the performance of Guardant Health's Shield™ test, which is targeted at the average-risk colorectal cancer screening market. Positive or improved data can bolster confidence in the test's efficacy and commercial viability.

This specific 8-K filing and the information furnished under Regulation FD are not considered 'filed' for legal purposes under Section 18 of the Securities Exchange Act of 1934. Therefore, it does not change the regulatory status or legal liability associated with the test itself, but rather serves as a disclosure of updated performance data.

The detailed data is available through the press release furnished as Exhibit 99.1 to this 8-K filing.